TScan Therapeutics, Inc. Common Stock
Symbol: TCRX (NASDAQ)
1.84
▼ (-0.54%) -0.010
Company Description:
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
Key Stats
- Today's Open: $1.84
- Today's High: $1.84
- Today's Low: $1.84
- Today's Volume: 1.04K
- Yesterday Close: $1.85
- Yesterday High: $1.86
- Yesterday Low: $1.76
- Yesterday Volume: 307.68K
- Last Min Volume: 40
- Last Min High: $1.84
- Last Min Low: $1.84
- Last Min VWAP: $1.84
Company Profile
- Name: TScan Therapeutics, Inc. Common Stock
- Website: https://www.tscan.com
- Listed Date: 2021-07-16
- Location: WALTHAM, MA
- Market Status: Active
- CIK Number: 0001783328
- SIC Code: 2836
- SIC description: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
- Market Cap: $104.42M
- Round Lot: 100
- Outstanding Shares: 56.75M
- Asset Type: CS
RECENT FILINGS FOR TCRX
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-09 | 8-K | View |
| 2025-08-22 | 3 | View |
| 2025-08-20 | 8-K | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-12 | SCHEDULE 13G/A | View |
| 2025-08-12 | 10-Q | View |
| 2025-08-12 | 8-K | View |
| 2025-07-16 | SCHEDULE 13G/A | View |
| 2025-07-02 | 4 | View |
| 2025-07-02 | 4 | View |
| 2025-07-02 | 4 | View |
| 2025-07-02 | 4 | View |
| 2025-07-02 | 4 | View |
| 2025-07-02 | 4 | View |
| 2025-07-02 | 8-K | View |
| 2025-05-21 | 4 | View |
| 2025-05-15 | SCHEDULE 13G/A | View |
| 2025-05-15 | SCHEDULE 13G/A | View |
| 2025-05-14 | ARS | View |
| 2025-05-14 | DEFA14A | View |
Latest News on TCRX